FR12C0064I2 - Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale - Google Patents

Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale

Info

Publication number
FR12C0064I2
FR12C0064I2 FR12C0064C FR12C0064C FR12C0064I2 FR 12C0064 I2 FR12C0064 I2 FR 12C0064I2 FR 12C0064 C FR12C0064 C FR 12C0064C FR 12C0064 C FR12C0064 C FR 12C0064C FR 12C0064 I2 FR12C0064 I2 FR 12C0064I2
Authority
FR
France
Prior art keywords
pharmaceutical compositions
injectable pharmaceutical
antitumor action
anthracenedione derivative
anthracenedione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0064C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapeutics Europe SRL
Original Assignee
Cell Therapeutics Europe SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Europe SRL filed Critical Cell Therapeutics Europe SRL
Publication of FR12C0064I1 publication Critical patent/FR12C0064I1/fr
Application granted granted Critical
Publication of FR12C0064I2 publication Critical patent/FR12C0064I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR12C0064C 2002-05-16 2012-10-25 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale Active FR12C0064I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
PCT/EP2003/004871 WO2003097101A1 (fr) 2002-05-16 2003-05-09 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale

Publications (2)

Publication Number Publication Date
FR12C0064I1 FR12C0064I1 (fr) 2012-12-14
FR12C0064I2 true FR12C0064I2 (fr) 2013-08-16

Family

ID=11449903

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0064C Active FR12C0064I2 (fr) 2002-05-16 2012-10-25 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale

Country Status (12)

Country Link
US (3) US20060199831A1 (fr)
EP (1) EP1503797B1 (fr)
JP (1) JP4624780B2 (fr)
AT (1) ATE381944T1 (fr)
AU (1) AU2003240613A1 (fr)
CA (1) CA2486001C (fr)
DE (1) DE60318310T2 (fr)
ES (1) ES2298521T3 (fr)
FR (1) FR12C0064I2 (fr)
IT (1) ITMI20021040A1 (fr)
MX (1) MXPA04011348A (fr)
WO (1) WO2003097101A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (fr) * 2008-04-04 2009-10-07 Ipsen Pharma Formulations liquides et lyophilisées
CN105769757B (zh) * 2016-03-26 2018-05-25 青岛市肿瘤医院 一种治疗非霍奇金淋巴瘤的注射液及其制备方法
CN105769776B (zh) * 2016-03-26 2018-05-11 青岛市肿瘤医院 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法
CN105997896B (zh) * 2016-05-28 2019-07-05 长沙秋点兵信息科技有限公司 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法
CN106176630B (zh) * 2016-08-03 2019-01-04 湖北丽益医药科技有限公司 一种注射用马来酸匹杉琼无菌粉末的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590124A (en) * 1967-06-27 1971-06-29 Us Navy Blood transfusion fluids having reduced turbulent friction properties
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
JPH08126685A (ja) * 1994-01-26 1996-05-21 Shionogi & Co Ltd デキストラン類の凍結乾燥方法
US5587382A (en) * 1994-03-28 1996-12-24 Boehringer Mannheim Italia, Spa 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity
EP1030839B1 (fr) * 1997-11-10 2004-02-04 G.D. SEARLE & CO. Emploi d'iminosucres alkyles pour traiter la resistance multiple aux anticancereux
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato

Also Published As

Publication number Publication date
DE60318310T2 (de) 2008-12-11
WO2003097101A1 (fr) 2003-11-27
JP2005530792A (ja) 2005-10-13
US9211262B2 (en) 2015-12-15
US20160256557A1 (en) 2016-09-08
CA2486001C (fr) 2010-04-13
ATE381944T1 (de) 2008-01-15
ITMI20021040A1 (it) 2003-11-17
MXPA04011348A (es) 2005-08-15
JP4624780B2 (ja) 2011-02-02
CA2486001A1 (fr) 2003-11-27
FR12C0064I1 (fr) 2012-12-14
EP1503797B1 (fr) 2007-12-26
ITMI20021040A0 (it) 2002-05-16
ES2298521T3 (es) 2008-05-16
EP1503797A1 (fr) 2005-02-09
US20060199831A1 (en) 2006-09-07
DE60318310D1 (de) 2008-02-07
US20110144147A1 (en) 2011-06-16
AU2003240613A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
IL153297A0 (en) Compounds and compositions for delivering active agents
HK1036970A1 (en) Compounds and compositions for delivering active agents.
HK1086832A1 (en) Substituted benzosulphonamides as potentiators of glutamate receptors
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DE69808765T2 (de) Verbindungen
IL162141A0 (en) Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy
WO2004005324A3 (fr) Composition peptidique pour le traitement de la dysfonction sexuelle
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
EP1503748A4 (fr) Medicaments servant a attenuer la neurotoxicite induite par le taxane
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
ES2189456T3 (es) Composicion acuosa inyectable.
TW200510370A (en) Urea derivatives
AP2001002369A0 (en) Pharmaceutical complex.
AU4558201A (en) Taxane anticancer agents
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
TW200504081A (en) N-sulfonylaminothiazole
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
RS50975B (sr) Kompozicije koje obuhvataju molekularno dispergovani drospirenon